Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of the National Cancer Institute

• Publication date

  2001-10-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JNCI/93.19.1449PMID 11584060
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.

  2001cited by this paper
• Selective Estrogen Receptor Modulation : A Personal Perspective 1

  2001cited by this paper
• The Lynn Sage Memorial Lecture: new developments in breast cancer management.

  2001cited by this paper
• Selective estrogen receptor modulation: a personal perspective.

  2001cited by this paper
• Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.

  2001cited by this paper
• Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.

  2001cited by this paper
• The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.

  2000cited by this paper
• Raloxifene hydrochloride.

  2000cited by this paper
• Uterine Effects of 3‐Year Raloxifene Therapy in Postmenopausal Women Younger Than Age 60

  2000cited by this paper
• Coronary and uterine vascular responses to raloxifene in the sheep.

  2000cited by this paper
• The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial

  2000cited by this paper
• Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer.

  2000cited by this paper
• A 12‐Month Comparative Study of Raloxifene, Estrogen, and Placebo on the Postmenopausal Endometrium

  2000cited by this paper
• Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.

  2000cited by this paper
• Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women.

  2000cited by this paper
• Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.

  2000cited by this paper
• Tamoxifen: a personal retrospective.

  2000cited by this paper
• Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol‐fed rabbits

  2000cited by this paper
• Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

  2000cited by this paper
• A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.

  2000cited by this paper
• Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

  2000cited by this paper
• Raloxifene and Estrogen Effects on Quality of Life in Healthy Postmenopausal Women: A Placebo‐Controlled Randomized Trial

  2000cited by this paper
• Effects of high dose raloxifene in selected patients with advanced breast carcinoma

  2000cited by this paper
• Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.

  2000cited by this paper
• Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.

  2000cited by this paper
• The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

  1999cited by this paper
• Comparative Analyses of Mechanistic Differences Among Antiestrogens1.

  1999cited by this paper
• The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.

  1999cited by this paper
• Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Comparative analyses of mechanistic differences among antiestrogens.

  1999cited by this paper
• Tamoxifen therapy for breast cancer and endometrial cancer risk.

  1999cited by this paper
• Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.

  1999cited by this paper
• The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.

  1999cited by this paper
• Validation studies for models projecting the risk of invasive and total breast cancer incidence.

  1999cited by this paper
• Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.

  1999cited by this paper
• Peptide antagonists of the human estrogen receptor.

  1999cited by this paper
• Effects of Estrogen and EstrogenProgestin on Mammographic Parenchymal Density

  1999cited by this paper
• Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

  1999cited by this paper
• Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening.

  1999cited by this paper
• Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

  1999cited by this paper
• Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.

  1999cited by this paper
• Estrogen receptor null mice: what have we learned and where will they lead us?

  1999cited by this paper
• Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.

  1999cited by this paper
• Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study.

  1999cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Mammographic densities and breast cancer risk.

  1998cited by this paper
• Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.

  1998cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.

  1998cited by this paper
• Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists.

  1998cited by this paper
• Differential Response of Estrogen Receptor α and Estrogen Receptor β to Partial Estrogen Agonists/Antagonists

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

  1998cited by this paper
• Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.

  1998cited by this paper
• The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

  1998cited by this paper
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

  1997cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• The Role of Hormone Replacement Therapy in the Risk for Breast Cancer and Total Mortality in Women with a Family History of Breast Cancer

  1997cited by this paper
• Postmenopausal hormone therapy and mortality.

  1997cited by this paper
• Postmenopausal hormone therapy and mortality.

  1997cited by this paper
• Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.

  1997cited by this paper
• Coronary heart disease mortality and adjuvant tamoxifen therapy.

  1997cited by this paper
• Molecular basis of agonism and antagonism in the oestrogen receptor

  1997cited by this paper
• Cloning of a novel receptor expressed in rat prostate and ovary.

  1996cited by this paper
• Nuclear receptor coactivators and corepressors.

  1996cited by this paper
• Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States

  1996cited by this paper
• Estrogen replacement therapy and risk of Alzheimer disease.

  1996cited by this paper
• Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

  1996cited by this paper
• Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques.

  1996cited by this paper
• Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.

  1994cited by this paper
• Hormonal treatment of postmenopausal women.

  1994cited by this paper
• Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

  1994cited by this paper
• Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.

  1993cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women

  1992cited by this paper
• Response after withdrawal of tamoxifen and progestogens in advanced breast cancer.

  1992cited by this paper
• Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

  1991cited by this paper
• Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.

  1991cited by this paper
• Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy.

  1990cited by this paper
• Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.

  1990cited by this paper
• Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers.

  1989cited by this paper
• Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.

  1989cited by this paper
• The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole

  1988cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1988cited by this paper
• Phase II evaluation of Ly156758 in metastatic breast cancer.

  1988cited by this paper
• Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.

  1988cited by this paper
• Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.

  1987cited by this paper
• Species-specific pharmacology of antiestrogens: role of metabolism.

  1987cited by this paper
• Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats

  1987cited by this paper
• Effects of anti-estrogens on bone in castrated and intact female rats

  1987cited by this paper

• Craniofacial fibrous dysplasia: Long-term postoperative outcomes in a retrospective case series with up to 40 years of follow-up.

  2025cites this paper
• Overview of biomembrane-derived nanoparticles as emerging drug delivery systems for treating bone aging diseases.

  2025cites this paper
• A Narrative Review on Breast Cancer Treatment Supported by Focused and Systemic Phytotherapy

  2025cites this paper
• New potential selective estrogen receptor modulators in traditional Chinese medicine for treating menopausal syndrome

  2024cites this paper
• Chemoprotective Effect of Bryodulcosigenin against 7,12-Dimethylbenz(a)anthracene-induced Breast Cancer via Suppression of Inflammation, Oxidative Stress, and Apoptosis

  2024cites this paper
• Synthesis and In-silico Studies of 4-Phenyl thiazol-2-amine Derivatives as Putative Anti-Breast Cancer Agents.

  2023cites this paper
• Anti-Osteoporosis Effects of the Fruit of Sea Buckthorn (Hippophae rhamnoides) through Promotion of Osteogenic Differentiation in Ovariectomized Mice

  2022cites this paper
• Aromatase Inhibition Increases Blood Pressure and Markers of Renal Injury in Female Rats.

  2022cites this paper
• Insights Into the Role of Epigenetic Factors Determining the Estrogen Response in Estrogen-Positive Ovarian Cancer and Prospects of Combining Epi-Drugs With Endocrine Therapy

  2022cites this paper
• Introduction: Estrogen Reconsidered: Exploring the Evidence for Estrogen's Benefits and Risks.

  2022cites this paper
• Effect of hormonal therapy on the otoconial changes caused by estrogen deficiency

  2022cites this paper
• Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.

  2022cites this paper
• Mass Spectrometry-Based Steroid Profiling: Meeting Unmet Clinical Needs.

  2021cites this paper
• Alginate based tamoxifen/metal dual core-folate decorated shell: Nanocomposite targeted therapy for breast cancer via ROS-driven NF-κB pathway modulation.

  2020cites this paper
• Tamoxifen exposure induces cleft palate in mice.

  2020cites this paper
• Secretory Endometrial Adenocarcinoma: A Rare Sequelae in a Postmenopausal Woman Following Tamoxifen Therapy for Breast Cancer

  2020cites this paper
• A Review on Selective Estrogen Receptor Modulators

  2019cites this paper
• Protective Effects of 2,3,5,4′-Tetrahydroxystilbene-2-O-β-d-glucoside on Ovariectomy Induced Osteoporosis Mouse Model

  2018cites this paper
• Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro

  2018cites this paper
• Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer

  2018cites this paper
• Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.

  2018cites this paper
• Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer

  2018cites this paper
• Tamoxifen usage correlates with increased risk of Parkinson’s disease in older women with breast cancer: a case–control study in Taiwan

  2017cites this paper
• Label-free detection of anti-estrogen receptor alpha and its binding with estrogen receptor peptide alpha by terahertz spectroscopy

  2017cites this paper
• Endocrine therapy inhibits proliferation and migration, promotes apoptosis and suppresses survivin protein expression in colorectal cancer cells

  2017cites this paper
• Regulation of osteoblast activity by Pyk2-targeted approaches

  2016cites this paper
• Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments

  2016cites this paper
• Kanamycin inhibits daidzein metabolism and abilities of the metabolites to prevent bone loss in ovariectomized mice

  2016cites this paper
• A combination of soy isoflavones and cello-oligosaccharides changes equol/O-desmethylangolensin production ratio and attenuates bone fragility in ovariectomized mice

  2016cites this paper
• Prediction of selective estrogen receptor beta agonist using open data and machine learning approach

  2016cites this paper
• Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells

  2015cites this paper
• Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites.

  2015cites this paper
• MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors

  2015cites this paper
• Antiosteoporosis Activity of New Oriental Medicine Preparation (Kyungokgo Mixed with Water Extract of Hovenia dulcis) on the Ovariectomized Mice

  2015cites this paper
• Review on the Role of Estrogen Receptors in Breast Cancer

  2015cites this paper
• A novel therapeutic approach with Caviunin-based isoflavonoid that en routes bone marrow cells to bone formation via BMP2/Wnt-β-catenin signaling

  2014cites this paper
• Effects of selective estrogen receptor modulators on plasma membrane estrogen receptors and catecholamine synthesis and secretion in cultured bovine adrenal medullary cells.

  2014cites this paper
• Turbo methanol extract inhibits bone resorption through regulation of T cell function.

  2014cites this paper
• Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer

  2014cites this paper
• FUNCTIONAL ANALYSIS OF 70% ETHANOLIC EXTRACT OF AKAR KELEMBAK (RHEUM OFFICINALE BAILL.) ON 3T3 L1 PREADIPOCYTE CELL LINES IN OSTEOGENIC MEDIUM

  2014cites this paper
• Effect of Red Clover on CYP Expression: An Investigation of Herb-Drug Interaction at Molecular Level

  2014cites this paper
• Regulation of UDP-Glucuronosyltransferase 1A1 Expression and Activity by MicroRNA 491-3p

  2014cites this paper
• Effects of herbal supplements on the bioactivation of chemotherapeutic agents

  2013cites this paper
• Health Beneficial Effects of Food Factors Can Be Applicable to Humans ?

  2013cites this paper
• Efecto del consumo de soja en la longevidad de ratones OF1 machos

  2013cites this paper
• Isoflavone metabolism and bone-sparing effects of daidzein-metabolites

  2013cites this paper
• Synthesis and Bioactivation of Selective Estrogen Receptor Modulators (SERMs)

  2013cites this paper
• Treating Health Risks or Putting Healthy Women at Risk: Controversies around Chemoprevention of Breast Cancer

  2013cites this paper
• Pharmacokinetic drug interactions between ondansetron and tamoxifen in female Sprague-Dawley rats with DMBA-induced mammary tumor.

  2013cites this paper
• Metabolites of Tamoxifen as the Basis of Drug Development

  2013cites this paper
• Predicting Disease Risk Using Bootstrap Ranking and Classification Algorithms

  2013cites this paper
• Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis

  2013cites this paper
• Endocrine Treatment for Breast Cancer

  2013cites this paper
• Estradiol receptors in breast cancer cells: associated co-factors as targets for new therapeutic approaches.

  2012cites this paper
• An Evidence-based Approach to Phytochemicals and Other Dietary Factors

  2012cites this paper
• The Tissue Specific Role of Estrogen and Progesterone in Human Endometrium and Mammary Gland

  2012cites this paper
• The Physiology and Pathophysiology of the Osteoclast

  2012cites this paper
• Mathematical models of cell cycle progression : applications to breast cancer cell lines.

  2012cites this paper
• Cooperating transcription factors mediate the function of estrogen receptor

  2012cites this paper
• Hormonothérapie des cancers du sein

  2011cites this paper
• [Hormone therapy and breast cancer].

  2011cites this paper
• Expression of the progesterone receptor, bcl-2 and bax in clomiphene citrate treated rat uteri

  2011cites this paper
• New Mechanism Based Anticancer Drugs for Treatment of Pancreatic and Bladder Cancers

  2011cites this paper
• Genetic rescue of nonclassical ERα signaling normalizes energy balance in obese Erα-null mutant mice.

  2011cites this paper
• Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients.

  2011cites this paper
• 17(lowercase beta)-estradiol and Tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in Helicobacter pylori-infected INS-GAS male mice

  2011cites this paper
• 17β-Estradiol and Tamoxifen Prevent Gastric Cancer by Modulating Leukocyte Recruitment and Oncogenic Pathways in Helicobacter Pylori–Infected INS-GAS Male Mice

  2011cites this paper
• A postmenopausal woman developed a giant endometrial polyp during Raloxifene treatment

  2011cites this paper
• Isoflavones suppress cyclic adenosine 3',5'-monophosphate regulatory element-mediated transcription in osteoblastic cell line.

  2011cites this paper
• Discerning the role of FOXA1 in mammary gland development and breast cancer

  2011cites this paper
• Protective Effect of Puerariae Radix on Ovariectomy-induced Bone Loss in Rats

  2011cites this paper
• Dietary Fat, Tamoxifen Use and Circulating Sex Hormones in Postmenopausal Breast Cancer Survivors

  2010cites this paper
• Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy

  2010cites this paper
• Sex Steroid Receptors in Immune Cells

  2010cites this paper
• Two Good Choices to Prevent Breast Cancer: Great Taste, Less Filling

  2010cites this paper
• Immunohistochemical Profile of Tamoxifen-Related Uterine Adenosarcomas

  2010cites this paper
• Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (

  2010cites this paper
• New Molecular Therapeutic Interventions: The Case of Breast Cancers

  2010cites this paper
• How to Think Like a Single Molecule: Obtaining Quantitative Measurements on Single DNA Molecules and Chromatin Fibers

  2010cites this paper
• SERMs in the prevention and treatment of postmenopausal osteoporosis: an update.

  2010cites this paper
• Alleviation of ovariectomy-induced osteoporosis in rats by Panax notoginseng saponins

  2010cites this paper
• Risk of Parkinson's disease after tamoxifen treatment

  2010cites this paper
• Designing the ideal selective estrogen receptor modulator-an achievable goal?

  2009cites this paper
• Relationships between age and gender differentials in health among older people in China

  2009cites this paper
• How computational methods try to disclose the estrogen receptor secrecy--modeling the flexibility.

  2009cites this paper
• Hormone Replacement Therapy: Real Concerns and False Alarms

  2009cites this paper
• Postmenopausal Hormone Therapy: : Differential Impact of Dose and Regimenson Hemostasis and Inflammation

  2009cites this paper
• Down‐regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells

  2009cites this paper
• Estrogen and Lithium: Facilitating Factors Involved in Brain Cell Signaling Pathways

  2009cites this paper
• Lithium: a potential estrogen signaling modulator

  2009cites this paper
• Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.

  2009cites this paper
• Control of rat tail skin temperature regulation by estrogen receptor-beta selective ligand.

  2009cites this paper
• [Protein display onto nano-sized bacterial magnetic particles for receptor analysis].

  2009cites this paper
• Natural products as aromatase inhibitors.

  2008cites this paper
• Estradiol Acts Directly on Bone Marrow Myeloid Progenitors to Differentially Regulate GM-CSF or Flt3 Ligand-Mediated Dendritic Cell Differentiation1

  2008cites this paper
• The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.

  2008cites this paper
• Pharmacophore mapping of arylbenzothiophene derivatives for MCF cell inhibition using classical and 3D space modeling approaches.

  2008cites this paper
• Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium.

  2008cites this paper
• Protective effect of apigenin on ovariectomy-induced bone loss in rats.

  2008cites this paper
• Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health

  2008cites this paper